• OPEN AN ACCOUNT
Indian Indices
Sensex
74,729.27 413.66
( 0.56%)
Global Indices
Nasdaq
52,191.76 549.28
(1.06%)
Dow Jones
7,764.37 24.43
(0.32%)
Hang Seng
65,489.63 1,063.68
(1.65%)
Nikkei 225
10,879.96 39.61
(0.37%)
Forex
USD-INR
95.08 -0.14
(-0.15%)
EUR-INR
106.23 -0.27
(-0.26%)
GBP-INR
125.74 -0.30
(-0.24%)
JPY-INR
0.60 0.00
(-0.23%)

EQUITY - MARKET SCREENER

Genesys International Corporation Ltd
Industry :  Computers - Software - Medium / Small
BSE Code
ISIN Demat
Book Value()
506109
INE727B01026
130.8364017
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
GENESYS
85.22
1561.29
EPS(TTM)
Face Value()
Div & Yield %
2.74
5
0
 

Indoco Remedies soars after Goa plant clears UK MHRA cGMP inspection
Sep 10,2026
The inspection of the facility, which manufactures solid oral dosage forms, was conducted from 7 September 2026 to 9 September 2026. The UK MHRA's current Good Manufacturing Practices (cGMP) inspection concluded with no critical or major observations, indicating compliance with the regulator's applicable manufacturing standards.

Indoco Remedies is a fully integrated, research-oriented pharmaceutical company with a strong global presence. It develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Top Indoco brands include Cyclopam, Febrex Plus, ATM, Rexidin M, Karvol Plus, Oxipod, Cital, Sensodent-K, Cital-Uti, Dropizin, Homide, Dentogel, Oxipod CV, Turbocort, Febrex, Cloben G, Tuspel LS, Noxa, MCBM 69, etc.

The company reported a consolidated net profit of Rs 64.99 crore in Q1 FY27 as against a net loss of Rs 35.79 crore in Q1 FY26. Revenue from operations rose 8.43% year on year to Rs 466.22 crore in the first quarter of FY27 from Rs 430.86 crore in the corresponding quarter last year.